| trastuzumab envedotin (DP303c) / CSPC Pharma |
NCT06313086: DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer |
|
|
| Recruiting | 3 | 442 | RoW | DP303c, trastuzumab emtansine, T -DM1 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | HER2-positive Breast Cancer | 12/25 | 02/28 | | |
| Not yet recruiting | 3 | 420 | NA | DP303c, Trastuzumab, Vinorelbine Tartrate, Capecitabine tablets | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | HER2-positive Advanced Breast Cancer | 01/26 | 07/28 | | |
NCT04828616: Study of DP303c Injection in Patients With Advanced Ovarian Cancer |
|
|
| Not yet recruiting | 2 | 104 | RoW | DP303c injection, DP303c | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Ovarian Cancer | 07/23 | 07/24 | | |
NCT05334810: DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer |
|
|
| Not yet recruiting | 2 | 191 | NA | DP303c, DP303c treatment | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | HER2-positive Breast Cancer | 12/23 | 12/23 | | |
NCT04826107: Study of DP303c Injection in Patients With Advanced or Metastatic Gastric Cancer |
|
|
| Not yet recruiting | 2 | 196 | NA | DP303c treatment, DP303c treatment（second-line of HER2-positive）, DP303c treatment （third-line of HER2-positive）, DP303c treatment（≥second-line of HER2 low expressing）, DP303c + PD-1/PD-L1 treatment | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Gastric Cancer | 08/24 | 12/24 | | |
NCT05810103: A Study of DP303c in Patients With HER2-positive Advanced Solid Tumors |
|
|
| Recruiting | 1 | 12 | RoW | DP303c | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | HER2-positive Advanced Solid Tumors | 12/23 | 03/24 | | |
